Differential regulation of IgG-NMO autoantibodies on S100Beta protein and disability in relapsing neuromyelitis optica

NeuroImmunoModulation

Volumn 17, Issue 3, 2010, Pages 177-179

  Robinson Agramonte, Maria A ^a   Gonçalves, Carlos Alberto Saravia ^b   Portela, Valmor L ^b   Saiz Hinarejos, A ^c   Oses, Pierre J ^b   Motta, Souza L ^b   Muller, A Pastoris ^b   Marquez Gonzalez, M E ^b   Gomes De Souza, Onofre D ^b  

^a CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Aquaporin 4; Demyelinating diseases; Devic's disease; Glial cell markers; Neuromyelitis optica; S 100beta

Indexed keywords

AQUAPORIN 4; AUTOANTIBODY; CELL MARKER; IMMUNOGLOBULIN G ANTIBODY; PROTEIN S100B;

ADULT; ANTIBODY DETECTION; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DEMYELINATING DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GLIA CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOREGULATION; MALE; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE;

ADULT; AQUAPORIN 4; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISABILITY EVALUATION; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOMODULATION; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; NEUROMYELITIS OPTICA; RECURRENCE; S100 PROTEINS;

EID: 76949092150     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000258717     Document Type: Conference Paper

References (11)

1. Jarius S, Aboul-Enein F, Waters P, et al: Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008; 131: 3072-3080.
2. Argyriou AA, Makris N: Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008; 118: 209-217.
3. Pentón-Rol G, Cervantes-Llanio M, Martinez- Sasnchez G, Cabrera-Gómez JA, Valenzuela- Silva CM, Ramirez-Nuñez O, Casanova- Orta M, Robinson-Agramonte MA, Lopategui-Cabezas I, Lopez-Saura A: TNF-α and IL-10 downregulation and marked oxidative stress in neuromyelitis optica. J Inflamm 2009; 6: 18-27.
4. Takano R, Tatsuro M, Toshiyuki T, Masahiro I, Kazuo F, Yasuto I: A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med 2008; 215: 55-59.
5. Van Eldik LJ, Wainwright MS: The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci 2003; 21: 97-108.
6. Cabrera-Gomez JA, Bonnan M, González- Quevedo A, Saiz-Hinarejos A, Marignier R, Olindo S, Graus F, Smadja D, Merle H, Thomas L, Gomez-García A, Cabre P: Neuromyelitis optica positive autoantibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West India. Mult Scler 2009; 15: 828-833.
7. Winherchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG: Revised diagnostic criteria for neuromyelitis óptica. Neurology 2006; 66: 1485-1489.
8. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1083; 33: 1444-1452.
9. Jarius S, Aboul-Enein F, Waters P, et al: Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008; 131: 3072-3080.
10. Lennon VA, Wingerchuck DM, Kryzer TJ, et al: A serum autoantibody marker of neuromyelitis optica distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
11. Marenholz I, Heizmann CW, Fritz G: S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322: 1111-1122.